Fulcrum Therapeutics, Inc.’s Net Profit Margin at a glance
Fulcrum Therapeutics, Inc. reports net profit margin of -12.2% for Dec 2024. The prior period recorded -3,470.1% (Dec 2023). Year over year the metric moved +3,457.9 pts (+99.6%). The rolling three-period average stands at -1,715.9%. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
-12.2% · Dec 2024
YoY movement
+3,457.9 pts (+99.6%)
Rolling average
-1,715.9%
Current Net Profit Margin
-12.2%
+3,457.9 pts
+99.6%
Rolling average
-1,715.9%
Latest Value
-12.2%
Dec 2024
YoY Change
+3,457.9 pts
Absolute
YoY Change %
+99.6%
Rate of change
3-Period Avg
-1,715.9%
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s net profit margin stands at -12.2% for Dec 2024. Year-over-year, the metric shifted by +3,457.9 pts, translating into a +99.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How net profit margin shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports net profit margin of -12.2%. Assess earnings efficiency, margin resiliency, and profitability drivers using annual historical margins.
Monitoring margin quality
Expanding margins signal improved cost control or pricing power. Contracting margins can point to rising input costs, pricing pressure, or product mix shifts.
Pair margin with growth metrics
Combine margin trends with revenue growth to understand whether the company is scaling efficiently or sacrificing profitability for expansion.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s net profit margin profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current net profit margin?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports net profit margin of -12.2%. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s net profit margin trending year over year?
Year-over-year, the figure shifts by +3,457.9 pts (+99.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does net profit margin matter for Fulcrum Therapeutics, Inc.?
Net profit margin measures how much of each dollar of revenue turns into net income after all expenses. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s net profit margin above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at -1,715.9%. Comparing the latest reading of -12.2% to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s net profit margin refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.